Bio-Rad Laboratories 对比 Bio-Techne
可添加、更换或移除公司，最多四家。
简而言之
- Bio-Rad Laboratories 规模更大:2025 财年营收 $2.6B，Bio-Techne 为 $1.2B，约为后者的 2.1 倍。
- Bio-Rad Laboratories 营收增长更快(0.7%，对方为 −0.4%)。
- Bio-Techne 每一美元销售额中留下的营业利润更多(营业利润率 20.7%，对方为 1.8%)。
- Bio-Techne 将更多销售额转化为自由现金流(自由现金流利润率 21.7%，对方为 14.5%)。
- Bio-Techne 的投入资本回报更高(9.2%，对方为 0.5%)。
| 最近财年 | BIO · FY25 | TECH · FY26 |
|---|---|---|
| 规模 | ||
| 市值 | $9.9B | $11.4B |
| 营收 | $2.6B | $1.2B |
| 自由现金流 | $375M | $263M |
| 净利润 | $760M | $182M |
| 增长 | ||
| 营收增长 | 0.7% | −0.4% |
| 5年增长率 | 0.3% | 5.5% |
| 股数变化 | −3.3% | −1.7% |
| 盈利能力 | ||
| 毛利率 | 51.9% | 65.8% |
| 营业利润率 | 1.8% | 20.7% |
| 净利率 | 29.4% | 15.0% |
| 自由现金流利润率 | 14.5% | 21.7% |
| 资本回报率 | 0.5% | 9.2% |
| 股本回报率 | 10.8% | 9.0% |
| 资产负债表 | ||
| 净债务 | −$329M | −$64.7M |
| 净债务 / EBITDA | −1.6x | −0.2x |
| 股息与回购 | $296M | $91.6M |
| 估值与质量 | ||
| 市盈率 | 46.3x | — |
| Piotroski F 分数 | 5 | 9 |
FY17
BIO $2.2B
TECH $563M
FY18
BIO $2.3B
TECH $643M
FY19
BIO $2.3B
TECH $714M
FY20
BIO $2.5B
TECH $739M
FY21
BIO $2.9B
TECH $931M
FY22
BIO $2.8B
TECH $1.1B
FY23
BIO $2.7B
TECH $1.1B
FY24
BIO $2.6B
TECH $1.2B
FY25
BIO $2.6B
TECH $1.2B
FY26
BIO —
TECH $1.2B
BIO
TECH
FY17
BIO 5.5%
TECH 21.4%
FY18
BIO −4.5%
TECH 21.2%
FY19
BIO 9.9%
TECH 20.6%
FY20
BIO 16.6%
TECH 21.3%
FY21
BIO 17.1%
TECH 25.5%
FY22
BIO 17.2%
TECH 26.8%
FY23
BIO 12.7%
TECH 26.3%
FY24
BIO 10.5%
TECH 17.8%
FY25
BIO 1.8%
TECH 8.4%
FY26
BIO —
TECH 20.7%
BIO
TECH
FY17
BIO −$7.2M
TECH $129M
FY18
BIO $156M
TECH $149M
FY19
BIO $359M
TECH $156M
FY20
BIO $476M
TECH $153M
FY21
BIO $536M
TECH $308M
FY22
BIO $81.6M
TECH $280M
FY23
BIO $218M
TECH $216M
FY24
BIO $290M
TECH $236M
FY25
BIO $375M
TECH $257M
FY26
BIO —
TECH $263M
BIO
TECH
FY17
BIO 5.0%
TECH 7.8%
FY18
BIO −2.4%
TECH 10.9%
FY19
BIO 4.3%
TECH 8.8%
FY20
BIO 4.8%
TECH 8.3%
FY21
BIO 3.6%
TECH 13.7%
FY22
BIO 3.5%
TECH 15.3%
FY23
BIO 3.1%
TECH 13.2%
FY24
BIO 2.9%
TECH 8.6%
FY25
BIO 0.5%
TECH 3.5%
FY26
BIO —
TECH 9.2%
BIO
TECH
各公司最近一个财年的数据；各公司财年结束月份不同。在越高(或越低)明显越好的行中，突出显示最佳值。不构成投资建议。